comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 14:08:19 - browse：29

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

WSS

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

What is artificial intelligence? Experts weigh in

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Cognito secures funding to test medical device for Alzheimer's

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Why Marc Tessier

focus

comprehensive

leisure time

23andMe had bad news about my health. I wish a person had delivered it

How Brent Saunders' Allergan experiment failed

Alkermes shareholders re

New chief aims to remake Sanofi Genzyme

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Pfizer's RSV vaccine recommended for approval in Europe

Trump demands the U.S. pay no more for drugs than other countries … again

Pfizer's RSV vaccine recommended for approval in Europe

In Memoriam: Notable people who died in 2023

A new deal aims to ramp up use of AI in rehab care decisions

entertainment

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

New chief aims to remake Sanofi Genzyme

A $475,000 price tag for a new cancer drug: crazy or meh?

Hey, doctors: Don't be no

How Brent Saunders' Allergan experiment failed

ARCH Venture Partners is raising $3 billion for a life sciences fund

focus

leisure time

Wikipedia

explore